Approach could also be applied to reversing aging and age-related diseases such as hearing loss and macular degeneration
Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.
“Although many studies have demonstrated that CRISPR/Cas9 can be applied as a powerful tool for gene therapy, there are growing concerns regarding unwanted mutations generated by the double-strand breaks through this technology,” says Juan Carlos Izpisua Belmonte, a professor in Salk’s Gene Expression Laboratory and senior author of the new paper, published in Cell on December 7, 2017. “We were able to get around that concern.”
In the original CRISPR/Cas9 system, the enzyme Cas9 is coupled with guide RNAs that target it to the right spot in the genome to create DSBs. Recently, some researchers have started using a “dead” form of Cas9 (dCas9), which can still target specific places in the genome, but no longer cuts DNA. Instead, dCas9 has been coupled with transcriptional activation domains—molecular switches—that turn on targeted genes. But the resulting protein—dCas9 attached to the activator switches—is too large and bulky to fit into the vehicle typically used to deliver these kinds of therapies to cells in living organisms, namely adeno-associated viruses (AAVs). The lack of an efficient delivery system makes it very difficult to use this tool in clinical applications.
Izpisua Belmonte’s team combined Cas9/dCas9 with a range of different activator switches to uncover a combination that worked even when the proteins were not fused to one another. In other words, Cas9 or dCas9 was packaged into one AAV, and the switches and guide RNAs were packaged into another. They also optimized the guide RNAs to make sure all the pieces ended up at the desired place in the genome, and that the targeted gene was strongly activated.
“The components all work together in the organism to influence endogenous genes,” says Hsin-Kai (Ken) Liao, a staff researcher in the Izpisua Belmonte lab and co–first author of the new paper. In this way, the technology operates epigenetically, meaning it influences gene activity without changing the DNA sequence.
To test the method, the researchers used mouse models of acute kidney injury, type 1 diabetes and a form of muscular dystrophy. In each case, they engineered their CRISPR/Cas9 system to boost the expression of an endogenous gene that could potentially reverse disease symptoms. In the case of kidney disease, they activated two genes known to be involved in kidney function, and observed not only increased levels of the proteins associated with those genes, but improved kidney function following an acute injury. For type 1 diabetes, they aimed to boost the activity of genes that could generate insulin-producing cells. Once again, the treatment worked, lowering blood glucose levels in a mouse model of diabetes. For muscular dystrophy, the researchers expressed genes that have been previously shown to reverse disease symptoms, including one particularly large gene that cannot easily be delivered via traditional virus-mediated gene therapies.
“We were very excited when we saw the results in mice,” adds Fumiyuki Hatanaka, a research associate in the lab and co–first author of the paper. “We can induce gene activation and at the same time see physiological changes.”
Izpisua Belmonte’s team is now working to improve the specificity of their system and to apply it to more cell types and organs to treat a wider range of human diseases, as well as to rejuvenate specific organs and to reverse the aging process and age-related conditions such as hearing loss and macular degeneration. More safety tests will be needed before human trials, they say.
The Latest on: CRISPR/Cas9 genome editing technology
American Heart Association reports Gene Editing Technology may improve accuracy of predicting individuals’ Heart Disease Risk
on July 12, 2018 at 2:06 am
For the first time, the study demonstrates the unique potential of combining stem cell-based disease modeling (Induced pluripotent stem cells) and CRISPR/Cas9-mediated genome editing technology as a p... […]
Patent Wars: Genome Editing
on July 11, 2018 at 7:53 pm
The hotly contested patent rights to CRISPR-Cas9 "genome editing" technology are still unsettled, as two groups of inventors await a decision from the U.S. Court of Appeals for the Federal Circuit on ... […]
CRISPR genome editing technology can correct alpha-1 antitrypsin deficiency
on July 2, 2018 at 9:30 am
Groundbreaking research demonstrates proof-of-concept for using CRISPR-Cas9 genome editing technology to correct the gene mutation responsible for alpha-1 antitrypsin (AAT) deficiency, successfully ma... […]
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
on June 19, 2018 at 6:18 am
This application broadly encompasses the CRISPR/Cas9 genome editing technology invented by Jennifer Doudna’s and Charpentier’s research teams. CRISPR Therapeutics, Intellia Therapeutics and Caribou Bi... […]
ERS Genomics : Licenses CRISPR/Cas9 Genome Editing Patents to NMI and NMI TT Pharmaservices
on May 31, 2018 at 5:00 am
ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology. NMI Natural and Medical Sciences In... […]
Genome Editing with CRISPR-Cas9 Prevents Angiogenesis of the Retina
on July 24, 2017 at 2:11 pm
In a report published online today in Nature Communications, the researchers present a novel gene-editing technique ... to impaired vision. CRISPR-Cas9 is a powerful new technology that can target and ... […]
via Google News and Bing News